Skip to content
PaperFren

Concept · medicine

Diabetes Care

6 studies2 discoveries

Diabetes care in this library covers mechanisms of insulin resistance, risks of developing type 2 diabetes, complications and cardiometabolic sequelae after gestational or type 2 diabetes, and tools that change day-to-day glycaemic management.

Mechanism studies, occupational risk cohorts, pregnancy sequelae, complication associations, and app trials answer different clinical questions. Mixing them into one “diabetes finding” erases those limits.

Studies

6

Findings

6

6 supporting · 0 challenging · 12 qualifying citations

Open tensions

2

Currently

What we know

  1. TXNIP rises with impaired glucose handling and tracks lower muscle glucose uptake.
  2. Insulin barely raises muscle ATP synthesis in insulin-resistant offspring of parents with diabetes.
  3. Longer rotating night-shift work associates with higher type 2 diabetes risk in nurses.
  4. Gestational diabetes marks markedly higher later type 2 diabetes risk in linked records.
  5. After type 2 diabetes, more low-risk lifestyle behaviours associate with fewer microvascular complications.

Largest unresolved question

Muscle mechanism studies, night-shift incidence, GDM sequelae, T2D complication associations, and a T1D app trial all sit under diabetes care but answer different estimands. They are complementary scopes, not interchangeable results.

Common misconceptions

  • Night-shift diabetes risk means lifestyle behaviours after diagnosis do not matter.

    Shift-work analyses concern incident T2D. Separate UK Biobank evidence associates healthier behaviour counts with fewer microvascular events among people who already have T2D.

  • TXNIP or ATP-flux findings are themselves a proven drug target trial result.

    Those papers are human physiology/mechanism studies. They do not show that intervening on TXNIP or ATP synthesis prevents diabetes in a clinical trial.

  • An app that lowers type 1 HbA1c generalises to type 2 complication prevention.

    The Glucose Buddy trial is type 1 glycaemia with feedback. T2D microvascular associations come from a different population and outcome.

Related